The presently disclosed subject matter generally relates to methods and compositions for modulating MAT II activity. More particularly, the presently disclosed subject matter relates to methods and compositions for inhibiting the expression of MAT II β subunit in a subject via RNAi by administering siRNA or shRNA molecules directed to MAT II β subunit. In some embodiments, the methods and compositions of the presently disclosed subject matter generally relates to the treatment of cancer. More particularly, the methods and compositions of the presently disclosed subject matter relates to the inhibition of MAT II β subunit for the treatment of leukemia.
